【荣昌生物(09995.HK)发盈警 预期2024年归母净亏损约14.7亿元 同比收窄约3%】荣昌生物(09995.HK)公布,预计2024 年度营业收入约人民币17.15亿元,同比增加约58%。 预计2024年度实现归属于母公司所有者的净亏损约14.7亿元,同比亏损减少约3%。

金融界
16 Jan
荣昌生物(09995.HK)公布,预计2024 年度营业收入约人民币17.15亿元,同比增加约58%。 预计2024年度实现归属于母公司所有者的净亏损约14.7亿元,同比亏损减少约3%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10